Abstract
The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota’s role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. This study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine significantly reduced the abundance of pathogenic bacteria in mice with CRC, such as Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplementation of FMT more effectively reversed the gut microbiota dysbiosis in CRC mice, as demonstrated by the ACE and Chao 1 indices, PCoA analysis, and enhanced normal biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, CD8+ T cells, and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC, as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ, and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
Data availability
The data for intestinal microbiota 16s rDNA are accessible at the National Centre for Biotechnology Information (https://www.ncbi.nlm.nih.gov/) under the accession number PRJNA1063875. The correspondence author will provide the raw data used to support this article’s conclusion.
References
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71 (3), 209–249 (2021).
Yang, Y. et al. Epidemiology and risk factors of colorectal cancer in China. Chin. J. Cancer Res. 32 (6), 729–741 (2020).
Rebecca, L. S., Kimberly, D. M., Ahmedin, J. & Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. (2020).
Mohsen, M., Jalil, M., Nourouz, D. & Abbas, A. Chronic Inflammation and Its Role in Colorectal Cancer Development. Oncogen. (2022).
Kolinsky, K. et al. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. Mol. Cancer Ther. 8 (1), 75–82 (2009).
Ishikawa, T. et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. 55 (7), 1091–1097 (1998).
Khan, M., Kleyner, R., Abbasi, S. & Haider, A. Capecitabine-Induced Enterocolitis Cureus ;14(3):e22855. (2022).
Montalban-Arques, A. & Scharl, M. Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. EBioMedicine 48, 648–655 (2019).
Han, Y. W. et al. Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells. Infect. Immun. 68 (6), 3140–3146 (2000).
Goodwin, A. C. et al. Jr. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. U S A. 108 (37), 15354–15359 (2011).
Kontizas, E. et al. Impact of Helicobacter pylori Infection and Its Major Virulence Factor CagA on DNA Damage Repair. Microorganisms 8(12), 2007 (2020).
Deng, Q. et al. Streptococcus bovis Contributes to the Development of Colorectal Cancer via Recruiting CD11b⁺TLR-4⁺ Cells. Med. Sci. Monit. 26, e921886 (2020).
Zhou, T. et al. Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer. NPJ Biofilms Microbiomes. 10 (1), 6 (2024).
Tukenmez, U., Aktas, B., Aslim, B. & Yavuz, S. The relationship between the structural characteristics of lactobacilli-EPS and its ability to induce apoptosis in colon cancer cells in vitro. Sci. Rep. 9 (1), 8268 (2019).
Nowak, A., Paliwoda, A. & Błasiak, J. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives. Crit. Rev. Food Sci. Nutr. 59 (21), 3456–3467 (2019).
Kang, X. et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut 72 (11), 2112–2122 (2023).
Zhu, L. et al. Fecal Short-Chain Fatty Acid Concentrations Increase in Newly Paired Male Marmosets (Callithrix jacchus). mSphere 5(5), e00794-20 (2020).
Li, C. et al. Probiotics, prebiotics, and synbiotics regulate the intestinal microbiota differentially and restore the relative abundance of specific gut microorganisms. J. Dairy. Sci. 103 (7), 5816–5829 (2020).
Lopès, A. et al. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. Int. J. Cancer. 146 (11), 3147–3159 (2020).
Wang, X. et al. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice. Nat. Microbiol. 10 (1), 169–184 (2025).
Jandhyala, S. M. et al. Role of the normal gut microbiota. World J. Gastroenterol. 21 (29), 8787–8803 (2015).
Kaźmierczak-Siedlecka, K. et al. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes. 11 (6), 1518–1530 (2020).
The, U. S., Food & Administration, D. FDA-approved fecal transplant therapy: FDA (2023). Available from: https://www.nebraskamed.com/health/conditions-and-services/
Neufert, C., Becker, C. & Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2 (8), 1998–2004 (2007).
Traina, T. A. et al. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis. 31 (1), 7–18 (2010).
Montalban-Arques, A. et al. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell. Host Microbe. 29 (10), 1573–88e7 (2021).
Biddle, A., Stewart, L., Blanchard, J. & Leschine, S. Untangling the Genetic Basis of Fibrolytic Specialization by Lachnospiraceae and Ruminococcaceae in Diverse Gut Communities. Diversity 5 (3), 627–640 (2013).
Maniar, K. S. V., Kumar, D., Moideen, A., Bhattacharyya, R. & Banerjee, D. Metformin: A candidate drug to control the epidemic of diabetes and obesity by way of gut microbiome modification. In: (eds Faintuch, J. & Faintuch, S.) Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications. Cambridge, MA: Academic 401–408. (2019).
Cao, H. et al. The secondary bile acid, deoxycholate accelerates intestinal adenoma-adenocarcinoma sequence in Apc (min/+) mice through enhancing Wnt signaling. Fam Cancer. 13 (4), 563–571 (2014).
Dossa, A. Y. et al. Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 310 (2), G81–92 (2016).
Larsen, J. M. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 151 (4), 363–374 (2017).
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51 (D1), D587–d92 (2023).
Neo, J. H. et al. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer. 10, 134 (2010).
Yin, H., Qu, J., Peng, Q. & Gan, R. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med. Microbiol. Immunol. 208 (5), 573–583 (2019).
Mohamed, H. I., Abdelrahim, E. M., Elsayed, A. M., Shaaban, S. M. & Eldahrouty, H. A. Relationship between hepatitis C virus infection and extrahepatic malignancies. Clin. Exp. Hepatol. 9 (3), 202–209 (2023).
Chen, T. C., Hinton, D. R., Zidovetzki, R. & Hofman, F. M. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab. Invest. 78 (2), 165–174 (1998).
Sipe, L. M., Chaib, M., Pingili, A. K., Pierre, J. F. & Makowski, L. Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity. Immunol. Rev. 295 (1), 220–239 (2020).
Ozaki, T. & Nakagawara, A. Role of p53 in Cell Death and Human Cancers. Cancers (Basel). 3 (1), 994–1013 (2011).
Zuzga, D. S. et al. Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. Int. J. Cancer. 130 (11), 2539–2548 (2012).
Zhang, S. et al. Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect. Front. Immunol. 12, 737849 (2021).
Kwon, M. J., Hong, E., Choi, Y., Kang, D. H. & Oh, E. S. Interleukin-1α promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression. Biochem. Biophys. Res. Commun. 446 (2), 487–492 (2014).
Kujawski, M. et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118 (10), 3367–3377 (2008).
Trinchieri, G. Interleukin-12 and interferon-gamma. Do they always go together? Am. J. Pathol. 147 (6), 1534–1538 (1995).
Huangfu, L., Li, R., Huang, Y. & Wang, S. The IL-17 family in diseases: from bench to bedside. Signal. Transduct. Target. Ther. 8 (1), 402 (2023).
Lim, C. & Savan, R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor. Rev. 25 (3), 257–271 (2014).
Lal, G. & Bromberg, J. S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 114 (18), 3727–3735 (2009).
Blaylock, R. L. Cancer microenvironment, inflammation and cancer stem cells: A hypothesis for a paradigm change and new targets in cancer control. Surg. Neurol. Int. 6, 92 (2015).
Thapa, R. J. et al. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol. Cell. Biol. 31 (14), 2934–2946 (2011).
Zhao, P. & Zhang, Z. TNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2. Oncol. Lett. 15 (3), 3820–3827 (2018).
Gulley, J. L. et al. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol. Oncol. 16 (11), 2117–2134 (2022).
Hendel, A., Hiebert, P. R., Boivin, W. A., Williams, S. J. & Granville, D. J. Granzymes in age-related cardiovascular and pulmonary diseases. Cell. Death Differ. 17 (4), 596–606 (2010).
Herbert, S. P. & Stainier, D. Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell. Biol. 12 (9), 551–564 (2011).
Mi, Z., Guo, H., Wai, P. Y., Gao, C. & Kuo, P. C. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27 (6), 1134–1145 (2006).
Jiang, Y., Chen, M., Nie, H. & Yuan, Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum. Vaccin Immunother. 15 (5), 1111–1122 (2019).
Koukourakis, G. V., Zacharias, G., Tsalafoutas, J., Theodoridis, D. & Kouloulias, V. Capecitabine for locally advanced and metastatic colorectal cancer: A review. World J. Gastrointest. Oncol. 2 (8), 311–321 (2010).
Park, D. J. et al. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 17 (1), 46–49 (2002).
Shao, M. et al. Capecitabine inhibits epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK/RANKL pathway. Oncol. Lett. 23 (3), 96 (2022).
Cheng, W. T., Kantilal, H. K. & Davamani, F. The Mechanism of Bacteroides fragilis Toxin Contributes to Colon Cancer Formation. Malays J. Med. Sci. 27 (4), 9–21 (2020).
Presley, L. L., Wei, B., Braun, J. & Borneman, J. Bacteria associated with immunoregulatory cells in mice. Appl. Environ. Microbiol. 76 (3), 936–941 (2010).
Fu, K. et al. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell 187 (4), 882–96e17 (2024).
Sasso, J. M. et al. Gut Microbiome-Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders. ACS Chem. Neurosci. 14 (10), 1717–1763 (2023).
Ormerod, K. L. et al. Genomic characterization of the uncultured Bacteroidales family S24-7 inhabiting the guts of homeothermic animals. Microbiome 4 (1), 36 (2016).
Jin, W. B. et al. Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome. Cell 185 (3), 547–62e22 (2022).
Liu, X. et al. Fucoidan Ameliorated Dextran Sulfate Sodium-Induced Ulcerative Colitis by Modulating Gut Microbiota and Bile Acid Metabolism. J. Agric. Food Chem. 70 (47), 14864–14876 (2022).
Shen, Z. et al. Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn’s disease. EBioMedicine 85, 104285 (2022).
Zhu, C. et al. Roseburia intestinalis inhibits interleukin–17 excretion and promotes regulatory T cells differentiation in colitis. Mol. Med. Rep. 17 (6), 7567–7574 (2018).
Nogal, A. et al. Circulating Levels of the Short-Chain Fatty Acid Acetate Mediate the Effect of the Gut Microbiome on Visceral Fat. Front. Microbiol. 12, 711359 (2021).
Sun, Y. & O’Riordan, M. X. Regulation of bacterial pathogenesis by intestinal short-chain Fatty acids. Adv. Appl. Microbiol. 85, 93–118 (2013).
van der Beek, C. M., Dejong, C. H. C., Troost, F. J., Masclee, A. A. M. & Lenaerts, K. Role of short-chain fatty acids in colonic inflammation, carcinogenesis, and mucosal protection and healing. Nutr. Rev. 75 (4), 286–305 (2017).
Zhang, X. et al. Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. Cell. Host Microbe. 31 (3), 418–32e8 (2023).
Tajiri, K. & Shimizu, Y. Gut bacteria may control development of hepatocellular carcinoma. Hepatobiliary Surg. Nutr. 6 (6), 417–419 (2017).
Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336 (6086), 1268–1273 (2012).
Akhtar, M. et al. Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation. Anim. Nutr. 8, 350–360 (2022).
Goldberg, M. F. et al. Salmonella Persist in Activated Macrophages in T Cell-Sparse Granulomas but Are Contained by Surrounding CXCR3 Ligand-Positioned Th1 Cells. Immunity 49 (6), 1090–102e7 (2018).
Ferraro, A., Boni, T. & Pintzas, A. EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene. PLoS One. 9 (12), e115276 (2014).
Round, J. L. & Mazmanian, S. K. Inducible Foxp3 + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. U S A. 107 (27), 12204–12209 (2010).
Kang, J. C., Chen, J. S., Lee, C. H., Chang, J. J. & Shieh, Y. S. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J. Surg. Oncol. 102 (3), 242–248 (2010).
Kravtsov, D. S., Erbe, A. K., Sondel, P. M. & Rakhmilevich, A. L. Roles of CD4 + T cells as mediators of antitumor immunity. Front. Immunol. 13, 972021 (2022).
Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 28 (1–2), 5–17 (2021).
Harty, J. T., Tvinnereim, A. R. & White, D. W. CD8 + T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18, 275–308 (2000).
Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (6264), 1084–1089 (2015).
Zhang, Q. et al. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8(+) T cell immunity. Cell. Metab. 35 (6), 943– (2023). – 60.e9.
Sordo-Bahamonde, C., Lorenzo-Herrero, S., Payer, Á. R., Gonzalez, S. & López-Soto, A. Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer. Int. J. Mol. Sci. 21(10), 3726 (2020).
Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42 (2), 344–355 (2015).
Kruse, B. et al. Tüting T. CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618 (7967), 1033–1040 (2023).
Yang, X. et al. Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment. Immunology 164 (3), 476–493 (2021).
Gershkovitz, M. et al. TRPM2 Mediates Neutrophil Killing of Disseminated Tumor Cells. Cancer Res. 78 (10), 2680–2690 (2018).
Cui, C. et al. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell 184 (12), 3163–77e21 (2021).
Schirmer, M. et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell. 167(4),1125-36.e8 (2016).
Francescone, R., Hou, V. & Grivennikov, S. I. Microbiome, inflammation, and cancer. Cancer J. 20 (3), 181–189 (2014).
Guler, R. et al. Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 29 (6), 1339–1346 (2011).
Malik, A. et al. IL-33 regulates the IgA-microbiota axis to restrain IL-1α-dependent colitis and tumorigenesis. J. Clin. Invest. 126 (12), 4469–4481 (2016).
Ellmerich, S., Djouder, N., Schöller, M. & Klein, J. P. Production of cytokines by monocytes, epithelial and endothelial cells activated by Streptococcus bovis. Cytokine 12 (1), 26–31 (2000).
Mirlekar, B. & Pylayeva-Gupta, Y. IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers (Basel) 13(2), 167 (2021).
Straus, D. S. & TNFα IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol. Cancer. 12, 78 (2013).
Thiele Orberg, E. et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 10 (2), 421–433 (2017).
Bernshtein, B. et al. IL-23-producing IL-10Rα-deficient gut macrophages elicit an IL-22-driven proinflammatory epithelial cell response. Sci. Immunol. 4(36), eaau6571 (2019).
Stanilov, N., Miteva, L., Mintchev, N. & Stanilova, S. High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int. J. Colorectal Dis. 24 (2), 151–157 (2009).
Lin, L. et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71 (23), 7226–7237 (2011).
Zhao, J. et al. Helicobacter pylori-induced STAT3 activation and signalling network in gastric cancer. Oncoscience 1 (6), 468–475 (2014).
Mook, O. R., Frederiks, W. M. & Van Noorden, C. J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta. 1705 (2), 69–89 (2004).
Hirayasu, H., Yoshikawa, Y., Tsuzuki, S. & Fushiki, T. A role of a lymphocyte tryptase, granzyme A, in experimental ulcerative colitis. Biosci. Biotechnol. Biochem. 71 (1), 234–237 (2007).
Yu, H. et al. Comprehensive analysis of gut microbiome and host transcriptome in chickens after Eimeria tenella infection. Front. Cell. Infect. Microbiol. 13, 1191939 (2023).
Kariya, Y. & Kariya, Y. Osteopontin in Cancer: Mechanisms and Therapeutic Targets. Int. J. Translational Med. 2 (3), 419–447 (2022).
Rao, G. et al. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin. Cancer Res. 19 (4), 785–797 (2013).
Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219–242 (2010).
Xu, H., Luo, H., Zhang, J., Li, K. & Lee, M. H. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. Gut Microbes. 15 (1), 2186114 (2023).
Kverka, M. et al. Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin. Exp. Immunol. 163 (2), 250–259 (2011).
Markman, J. L. & Shiao, S. L. Impact of the immune system and immunotherapy in colorectal cancer. J. Gastrointest. Oncol. 6 (2), 208–223 (2015).
Gao, Y. et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal. Transduct. Target. Ther. 6 (1), 398 (2021).
Mezzapelle, R. et al. CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy. Cancers (Basel), 14(9), 2314 (2022).
Funding
This work was supported by the National Natural Science Foundation of China (NSFC81903631, NSFC82020108022, NSFCU23A20521) and the Youth Innovation Fund of University in Heilongjiang (UNPYSCT14 2018065).
Author information
Authors and Affiliations
Contributions
Muhammad Arshad.: Investigation, editing, sampling, analyzing, methodology, reporting the results, and writing–original draft. Chong-Yuan Zhang.: Analyzing, and methodology. Zhan-Kui Gao.: Investigation, methodology. Dan-Qi Xu.: Investigation. Chao-Yuan Fan.: Investigation. Bo-Wen Zhang.: Investigation. Jia-Xin Geng.: Investigation. Hui Sun.: Methodology. Yang Li.: Methodology. Aleksandr Kotusov.: Analyzing. Ning Zhang.: Funding acquisition. Shu-Lin Liu.: Supervision, and funding acquisition. Xiao-Qin Mu.: Conceptualization, review and editing, supervision, and funding acquisition. All authors contributed to the article and approved the submitted version.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
All animal procedures were conducted in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee of Harbin Medical University (protocol number IRB3079724) and were performed in compliance with the ARRIVE guidelines.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Arshad, M., Zhang, CY., Gao, ZK. et al. Capecitabine combined with fecal microbiota transplantation prevents colorectal cancer progression through correction of microbial dysbiosis and immune regulation. Sci Rep (2026). https://doi.org/10.1038/s41598-026-43626-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-43626-1
